FLT3 and acute myeloid leukemia: Stone and colleagues120 conducted a randomized phase III RATIFY trial (CALGB 10603) in 717 patients <60 years of age with newly diagnosed FLT3-mutated AML (FLT3-ITD and/or FLT3-TKD; median age 48 years; range 18 to 60 years) with the combination of 3 + 7 with or without midostaurin.